Tvardi Therapeutics (NASDAQ:TVRD) Downgraded to “Strong Sell” Rating by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

Other research analysts have also recently issued reports about the stock. HC Wainwright began coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $3.20 on Friday. Tvardi Therapeutics has a one year low of $1.50 and a one year high of $43.65. The business has a fifty day moving average of $3.04 and a two-hundred day moving average of $3.50. The company has a market cap of $30.02 million, a P/E ratio of -1.03 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Sell-side analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently bought and sold shares of TVRD. Russell Investments Group Ltd. lifted its position in shares of Tvardi Therapeutics by 1,351.5% in the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after acquiring an additional 14,866 shares in the last quarter. Squarepoint Ops LLC raised its stake in Tvardi Therapeutics by 534.3% in the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after purchasing an additional 43,619 shares during the last quarter. Jane Street Group LLC acquired a new position in Tvardi Therapeutics in the 4th quarter valued at about $204,000. Goldman Sachs Group Inc. lifted its holdings in Tvardi Therapeutics by 37.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock valued at $142,000 after purchasing an additional 9,102 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Tvardi Therapeutics in the 2nd quarter valued at about $80,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.